Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenic purpura: meta-analysis

References

• Kühne T, Berchtold W, Michaels LA, Wu R, Donato H, Espina B, Tamary H, Rodeghiero F, Chitlur M, Rischewski J. Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group. Haematologica 2011;96(12):1831–1837. doi:10.3324/haematol.2011.050799
   PubMed Web of Science ®Google Scholar
• Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004;76(6):628–638. doi:10.1016/j.clpt.2004.08.010
   PubMed Web of Science ®Google Scholar
• Escudero Vilaplana V, Aragonés JH, Fernandez-Llamazares CM, Bieler CB, Rodríguez SM, Sáez MS. Use of romiplostim for primary immune thrombocytopenia in children. Pediatr Hematol Oncol 2012;29(2):197–205. doi:10.3109/08880018.2011.629401
   PubMed Web of Science ®Google Scholar
• Pasquet M, Aladjidi N, Guiton C, Courcoux MF, Munzer M, Auvrignon A, Lutz P, Ducassou S, Leroy G, Munzer C, et al. Romiplostim in children with chronic immune thrombocytopenia (ITP): the French experience. Br J Haematol 2014;164(2):266–271. doi:10.1111/bjh.12609
   PubMed Web of Science ®Google Scholar
• Mokhtar GM, Tantawy AA, El Sherif NH. Romiplostim therapy in children with unresponsive chronic immune thrombocytopenia. Platelets 2012;23(4):264–273. doi:10.3109/09537104.2011.619601
   PubMed Web of Science ®Google Scholar
• D’Orazio JA, Neely J, Farhoudi N. ITP in children: pathophysiology and current treatment approaches. J Pediatr Hematol Oncol 2013;35(1):1–13. doi:10.1097/MPH.0b013e318271f457
   PubMedGoogle Scholar
• Neunert C, Despotovic J, Haley K, Lambert MP, Nottage K, Shimano K, Bennett C, Klaassen R, Stine K, Thompson A, et al. Thrombopoietin receptor agonist use in children: data from the pediatric ITP consortium of North America ICON2 Study. Pediatr Blood Cancer 2016;63(8):1407–1413. doi:10.1002/pbc.26003
   PubMed Web of Science ®Google Scholar
• Wang L, Gao Z, Chen X-P, Zhang H-Y, Yang N, Wang F-Y,  Guan L-X, Gu Z-Y, Zhao S-S, Luo L, et al. Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: a systematic review and meta-analysis. Sci Rep 2016;6. doi:10.1038/srep39003
   Web of Science ®Google Scholar
• Nguyen -T-TL, Palmaro A, Montastruc F, Lapeyre-Mestre M, Moulis G. Signal for thrombosis with eltrombopag and romiplostim: a disproportionality analysis of spontaneous reports within VigiBase®. Drug Saf 2015;38(12):1179–1186. doi:10.1007/s40264-015-0337-1
   PubMed Web of Science ®Google Scholar
• Garzon AM, Mitchell WB. Use of thrombopoietin receptor agonists in childhood immune thrombocytopenia. Front Pediatr 2015;3:70. doi:10.3389/fped.2015.00070
   PubMed Web of Science ®Google Scholar
• Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology 1999;37–48. doi:10.1097/00001648-199901000-00008
   PubMed Web of Science ®Google Scholar
• Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj 1997;315(7109):629–634.
   PubMed Web of Science ®Google Scholar
• Terrin N, Schmid CH, Lau J, Olkin I. Adjusting for publication bias in the presence of heterogeneity. Stat Med 2003;22(13):2113–2126. doi:10.1002/sim.1461
   PubMed Web of Science ®Google Scholar
• Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. Bmj 2015;349:g7647. doi:10.1136/bmj.g7647
   PubMed Web of Science ®Google Scholar
• Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Raj A, Williams B, Beam D, Morales J, Rose MJ, et al. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Lancet 2016;388(10039):45–54. doi:10.1016/S0140-6736(16)00279-8
   Google Scholar
• Bussel JB, Buchanan GR, Nugent DJ, Gnarra DJ, Bomgaars LR, Blanchette VS, Wang YM, Nie K, Jun S., et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood 2011;118(1):28–36. doi:10.1182/blood-2010-10-313908
   Google Scholar
• Elalfy MS, Abdelmaksoud AA, Eltonbary KY. Romiplostim in children with chronic refractory ITP: randomized placebo controlled study. Ann Hematol 2011;90(11):1341–1344. doi:10.1007/s00277-011-1172-9
   Google Scholar
• Grainger JD, Locatelli F, Chotsampancharoen T, Donyush E, Pongtanakul B, Komvilaisak P, Sosothikul D, Drelichman G, Sirachainan N, Holzhauer S, et al. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet 2015;386(10004):1649–1658. doi:10.1016/S0140-6736(15)61107-2
   Google Scholar
• Bussel JB, De Miguel PG, Despotovic JM, Grainger JD, Sevilla J, Blanchette VS, Krishnamurti L, Connor P, David M9, Boayue KB et al. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol 2015;2(8):e315–e25. doi:10.1016/S2352-3026(15)00114-3
   Google Scholar
• Higgins Jp, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD,  Savovic J, Schulz KF, Weeks L, Sterne JA, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. Bmj 2011;343:d5928. doi:10.1136/bmj.d5928
   PubMedGoogle Scholar
• Elgebaly AS, El Ashal G, Elfil M, Menshawy A. Tolerability and efficacy of eltrombopag in chronic immune thrombocytopenia meta-analysis of randomized controlled trials. Clin Appl Thrombosis/Hemostasis 2017;23(8):928-937.doi:10.1177/1076029616663849
   Google Scholar
• Zeng Y, Duan X, Xu J, Ni X. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura. Cochrane Lib 2011; (7):CD008235. doi:10.1002/14651858
   Google Scholar